119 related articles for article (PubMed ID: 28470625)
1. An anti-amoebic vaccine: generation of the recombinant antigen LC3 from Entamoeba histolytica linked to mutated exotoxin A (PEΔIII) via the Pichia pastoris system.
Martínez-Hernández SL; Cervantes-García D; Muñoz-Ortega M; Aldaba-Muruato LR; Loera-Muro VM; Ascacio-Martínez JA; de Jesús Loera-Arias M; de Oca-Luna RM; Ventura-Juárez J
Biotechnol Lett; 2017 Aug; 39(8):1149-1157. PubMed ID: 28470625
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the PE
Martínez-Hernández SL; Becerra-González VM; Muñoz-Ortega MH; Loera-Muro VM; Ávila-Blanco ME; Medina-Rosales MN; Ventura-Juárez J
J Immunol Res; 2021; 2021():6697900. PubMed ID: 33824880
[No Abstract] [Full Text] [Related]
3. Fusion protein vaccine by domains of bacterial exotoxin linked with a tumor antigen generates potent immunologic responses and antitumor effects.
Liao CW; Chen CA; Lee CN; Su YN; Chang MC; Syu MH; Hsieh CY; Cheng WF
Cancer Res; 2005 Oct; 65(19):9089-98. PubMed ID: 16204084
[TBL] [Abstract][Full Text] [Related]
4. Cloning, expression and characterization of recombinant exotoxin A-flagellin fusion protein as a new vaccine candidate against Pseudomonas aeruginosa infections.
Tanomand A; Farajnia S; Najar Peerayeh S; Majidi J
Iran Biomed J; 2013; 17(1):1-7. PubMed ID: 23279828
[TBL] [Abstract][Full Text] [Related]
5. Systematic comparison of single-chain Fv antibody-fusion toxin constructs containing Pseudomonas Exotoxin A or saporin produced in different microbial expression systems.
Della Cristina P; Castagna M; Lombardi A; Barison E; Tagliabue G; Ceriotti A; Koutris I; Di Leandro L; Giansanti F; Vago R; Ippoliti R; Flavell SU; Flavell DJ; Colombatti M; Fabbrini MS
Microb Cell Fact; 2015 Feb; 14():19. PubMed ID: 25889802
[TBL] [Abstract][Full Text] [Related]
6. Preparation of recombinant atoxic form of exotoxin A from Pseudomonas aeruginosa.
Kaloshin AA; Isakov MA; Mikhailova NA; Vertiev JV
Bull Exp Biol Med; 2013 Jan; 154(3):346-50. PubMed ID: 23484197
[TBL] [Abstract][Full Text] [Related]
7. Isolation and characterizations of a novel recombinant scFv antibody against exotoxin A of Pseudomonas aeruginosa.
Shadman Z; Farajnia S; Pazhang M; Tohidkia M; Rahbarnia L; Najavand S; Toraby S
BMC Infect Dis; 2021 Mar; 21(1):300. PubMed ID: 33761869
[TBL] [Abstract][Full Text] [Related]
8. Non-toxic Pseudomonas aeruginosa exotoxin A expressing the FMDV VP1 G-H loop for mucosal vaccination of swine against foot and mouth disease virus.
Challa S; Barrette R; Rood D; Zinckgraf J; French R; Silbart L
Vaccine; 2007 Apr; 25(17):3328-37. PubMed ID: 17276557
[TBL] [Abstract][Full Text] [Related]
9. [Immunobiological properties of recombinant atoxic forms of the Pseudomonas aeruginosa exotoxin A].
Isakov MA; Soldatenkova AS; Kaloshin AA; Mikhaĭlova NA
Zh Mikrobiol Epidemiol Immunobiol; 2011; (2):37-42. PubMed ID: 21598613
[TBL] [Abstract][Full Text] [Related]
10. An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes.
Onda M; Beers R; Xiang L; Nagata S; Wang QC; Pastan I
Proc Natl Acad Sci U S A; 2008 Aug; 105(32):11311-6. PubMed ID: 18678888
[TBL] [Abstract][Full Text] [Related]
11. [Construction, expression and immunogenicity analysis of a fusion protein containing M2e of influenza A virus fused to a modified Pseudomonas aeruginosa exotoxin A].
Xu Y; Yao LH; Chen AJ; Guo JQ; Liu XY; Bo H; Liu LQ; Shu YL; Zhang ZQ
Bing Du Xue Bao; 2010 May; 26(3):189-94. PubMed ID: 20572339
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of immunization against cancer using chimeric antigens.
Engelhorn ME; Guevara-Patiño JA; Merghoub T; Liu C; Ferrone CR; Rizzuto GA; Cymerman DH; Posnett DN; Houghton AN; Wolchok JD
Mol Ther; 2008 Apr; 16(4):773-81. PubMed ID: 18301399
[TBL] [Abstract][Full Text] [Related]
13. EGF ligand fused to truncated Pseudomonas aeruginosa exotoxin A specifically targets and inhibits EGFR‑positive cancer cells.
Hashimi SM; Grant B; Alqurashi N; Alowaidi F; Wei MQ
Oncol Rep; 2018 Nov; 40(5):2690-2697. PubMed ID: 30226622
[TBL] [Abstract][Full Text] [Related]
14. The development of a novel cancer immunotherapeutic platform using tumor-targeting mesenchymal stem cells and a protein vaccine.
Wei HJ; Wu AT; Hsu CH; Lin YP; Cheng WF; Su CH; Chiu WT; Whang-Peng J; Douglas FL; Deng WP
Mol Ther; 2011 Dec; 19(12):2249-57. PubMed ID: 21792181
[TBL] [Abstract][Full Text] [Related]
15. Recombinant CD64-specific single chain immunotoxin exhibits specific cytotoxicity against acute myeloid leukemia cells.
Tur MK; Huhn M; Thepen T; Stöcker M; Krohn R; Vogel S; Jost E; Osieka R; van de Winkel JG; Fischer R; Finnern R; Barth S
Cancer Res; 2003 Dec; 63(23):8414-9. PubMed ID: 14679004
[TBL] [Abstract][Full Text] [Related]
16. Conjugating recombinant proteins to Pseudomonas aeruginosa ExoProtein A: a strategy for enhancing immunogenicity of malaria vaccine candidates.
Qian F; Wu Y; Muratova O; Zhou H; Dobrescu G; Duggan P; Lynn L; Song G; Zhang Y; Reiter K; MacDonald N; Narum DL; Long CA; Miller LH; Saul A; Mullen GE
Vaccine; 2007 May; 25(20):3923-33. PubMed ID: 17428587
[TBL] [Abstract][Full Text] [Related]
17. [Pseudomonas aeruginosa recombinant proteins: effect on mice cytokine profile].
Soldatenkova AV; Geĭderova LA; Akhmatova NK; Mikhaĭlova NA
Zh Mikrobiol Epidemiol Immunobiol; 2013; (6):80-7. PubMed ID: 24605680
[TBL] [Abstract][Full Text] [Related]
18. Combination of the PI3K inhibitor ZSTK474 with a PSMA-targeted immunotoxin accelerates apoptosis and regression of prostate cancer.
Baiz D; Hassan S; Choi YA; Flores A; Karpova Y; Yancey D; Pullikuth A; Sui G; Sadelain M; Debinski W; Kulik G
Neoplasia; 2013 Oct; 15(10):1172-83. PubMed ID: 24204196
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients.
Onda M; Nagata S; FitzGerald DJ; Beers R; Fisher RJ; Vincent JJ; Lee B; Nakamura M; Hwang J; Kreitman RJ; Hassan R; Pastan I
J Immunol; 2006 Dec; 177(12):8822-34. PubMed ID: 17142785
[TBL] [Abstract][Full Text] [Related]
20. Recombinant chimeric vaccine composed of PRRSV antigens and truncated Pseudomonas exotoxin A (PE-K13).
Yang HP; Wang TC; Wang SJ; Chen SP; Wu E; Lai SQ; Chang HW; Liao CW
Res Vet Sci; 2013 Oct; 95(2):742-51. PubMed ID: 23712024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
